Literature DB >> 8830028

Human tumor rejection antigens MAGE.

K Itoh1, A Hayashi, M Nakao, T Hoshino, N Seki, S Shichijo.   

Abstract

Characterization of the MAGE genes has facilitated a molecular approach to identification of the genes encoding tumor-rejection antigens expressed on human cancer cells. MAGE proteins are normal tissue antigens compartmentalized in testicular cells that play an important role in the early phase of spermatogenesis. MAGE-1, -2, -3, -4, and -6 genes are preferentially expressed in many different cancers at both the mRNA and protein levels. More than half of human cancers of various histologic type express at least one of these MAGE genes. Demethylation induces MAGE antigens in cells, suggesting that MAGE genes are important developmentally regulated genes under methylating control. Thus, genetic instability in cells causing loss of this methylating control could result in the preferential expression of MAGE genes in cancer cells. Therefore, MAGE gene products may be appropriate target molecules for development of new cancer vaccine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830028     DOI: 10.1093/oxfordjournals.jbchem.a021252

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  3 in total

1.  MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.

Authors:  G F Hofbauer; C Schaefer; C Noppen; R Böni; J Kamarashev; F O Nestle; G C Spagnoli; R Dummer
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

2.  CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo.

Authors:  Songbing He; Liang Wang; Yugang Wu; Dechun Li; Yanyun Zhang
Journal:  J Exp Clin Cancer Res       Date:  2010-04-27

3.  Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours.

Authors:  A A Jungbluth; E Stockert; Y T Chen; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; K J Busam; L J Old
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.